


## Supplementary Information

**Table S1.** The half maximal inhibitory concentration (IC<sub>50</sub>) and 50% hemolysis (HC<sub>50</sub>) of BJA-95 on normal cells compared with K KU-213 cell.

Cell type	Cell lines	IC <sub>50</sub> (μg/ml)
Cholangiocarcinoma cell	KKU-213	7.1±1.3
Normal cholangiocyte	MMNK-1	10.5±1.6*
Human breast epithelial cell	MCF-10A	16.1±1.4**
Fibroblast cell	3T3-L1	11.6±1.1*
Blood cell	Peripheral blood mononuclear cells (PBMCs)	13.8±1.7**
		HC <sub>50</sub> (mg/ml)
Blood cell	Red blood cells (RBCs)	0.5±0.1****

Notes: Results are shown as mean ± SD from repeated three independent experiments for K KU-213 and MMNK-1 cell lines. The IC<sub>50</sub> and HC<sub>50</sub> on MCF-10A, 3T3-L1, PBMCs and RBCs were referred from our previous study <sup>19</sup>. (\*)  $p < 0.05$ , (\*\*)  $p < 0.01$ , (\*\*\*)  $p < 0.001$ , (\*\*\*\*)  $p < 0.0001$  significantly higher than the value of K KU-213 cells.



**Figure S1.** Representative photos of hematoxylin and eosin (H&E) staining of liver tissues. The BJA-95 treatment showed no discernible toxicity on mice liver cells.